Role of Vitamin D Receptor Activators in Cardio-Renal Syndromes

Seminars in Nephrology

Volumn 32, Issue 1, 2012, Pages 63-69

  Cozzolino, Mario ^a   Bruschetta, Elena ^a   Stucchi, Andrea ^b   Ronco, Claudio ^b   Cusi, Daniele ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b SAN BORTOLO HOSPITAL   (Italy)

Author keywords

Chronic kidney disease; Dialysis; Mineral metabolism; Vitamin d

Indexed keywords

22 OXACALCITRIOL; ALFACALCIDOL; ANGIOTENSIN RECEPTOR ANTAGONIST; CALCITRIOL; COLECALCIFEROL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOXERCALCIFEROL; ERGOCALCIFEROL; PARICALCITOL; PLACEBO; VITAMIN D; VITAMIN D RECEPTOR;

ARTICLE; BLOOD PRESSURE REGULATION; BLOOD VESSEL CALCIFICATION; CARDIORENAL SYNDROME; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; DIABETES MELLITUS; DRUG DETERMINATION; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MECHANISM; DRUG STRUCTURE; ENZYME INHIBITION; HEART PROTECTION; HUMAN; NONHUMAN; PERIPHERAL VASCULAR DISEASE; PRIORITY JOURNAL; RENAL PROTECTION; TREATMENT RESPONSE; VITAMIN D DEFICIENCY;

CARDIO-RENAL SYNDROME; ERGOCALCIFEROLS; HUMANS; HYPERPARATHYROIDISM, SECONDARY; HYPERPHOSPHATEMIA; HYPOCALCEMIA; KIDNEY; PARATHYROID GLANDS; PARATHYROID HORMONE; RECEPTORS, CALCITRIOL; RENAL INSUFFICIENCY, CHRONIC; VASCULAR CALCIFICATION; VITAMIN D; VITAMIN D DEFICIENCY;

EID: 84857375103     PISSN: 02709295     EISSN: 15584488     Source Type: Journal    
DOI: 10.1016/j.semnephrol.2011.11.009     Document Type: Article

References (47)

1. Brancaccio D., Bommer J., Coyne D. Vitamin D receptor activator selectivity in the treatment of the secondary hyperparathyroidism. Drugs 2007, 67:14.
2. Ronco C., Cozzolino M. Mineral metabolism abnormalities and vitamin D receptor activation in cardio-renal syndromes. Heart Fail Rev 2011 Feb 13, [Epub ahead of print].
3. Vanga S.R., Good M., Howard P.A., Vacek J.L. Role of vitamin D in cardiovascular health. Am J Cardiol 2010, 106:798-805.
4. DeLuca H.F. Overview of general physiologic features and functions of vitamin D. Am J Clin Nutr 2004, 80:1689S-1696S.
5. Pilz S., Tomaschitz A., Ritz E., Pieber T.R. Vitamin D status and arterial hypertension: a systematic review. Nat Rev Cardiol 2009, 6:621-630.
6. Timpini A., Pini L., Tantucci C., Cossi S., Grassi V. Vitamin D and health status in elderly. Intern Emerg Med 2011, 6:11-21.
7. Shari S., Bassuk J.A., Manson J. Does Vitamin D protect against cardiovascular disease?. J Cardiovasc Trans Res 2009, 2:245-250.
8. Nakane M., Ma J., Rose A.E., et al. Differential effects of vitamin D analogs on calcium transport. J Steroid Biochem Mol Biol 2007, 103:84-89.
9. Nakane M., Fey T.A., Dixon D.B., et al. Differential effects of vitamin D analogs on bone formation and resorption. J Steroid Biochem Mol Biol 2006, 98:72-77.
10. Cozzolino M., Fallabrino G., Pasho S., Olivi L., Ciceri P., Volpi E., et al. Importance of vitamin D receptor activation in clinical practice. Contrib Nephrol 2009, 163:213-218.
11. Cozzolino M., Brandenburg V. Paricalcitol and outcome: a manual on how a vitamin D receptor activator (VDRA) can help us to get down the "U". Clin Nephrol 2009, 71:593-601.
12. Petrie M.S., Harrie T.E., Schwartz G.G., et al. Production of plasminogen activator inhibitor 1 (PAI-1) by endothelial cells: differential responses to calcitriol and paricalcitol. J Thromb Haemost 2004, 2:2266-2267.
13. Nordt T.K., Peter K., Ruef J., et al. Plasminogen activator inhibitor type 1 (PAI-1) and its role in cardiovascular disease. Thromb Haemost 1999, 82(Suppl 1):14-18.
14. Mizobuchi M, Finch JL, Martin DR, et al. Differential effects of vitamin D receptor activators on vascular calcification in uremic rats. Kidney Int. [Epub Jun 2007].
15. Dobrez D.G., Mathes A., Amdhal M., Marx S.E., Melnick J.Z., Sprague S.M. Paricalcitol-treated patients experience improved hospitalization outcomes compared with calcitriol-treated patients in real-world clinical settings. Nephrol Dial Transplant 2004, 19:1174-1181.
16. Sprague S.M., Llach F., Amdhal M., et al. Paricalcitol versus calcitriol in the treatment of hyperparathyroidism. Kidney Int 2003, 63:1483-1490.
17. Wang T.J., Pencina M.J., Booth S.L., Jacques P.F., Ingelsson E., Lanier K., et al. Vitamin D deficiency and risk of cardiovascular disease. Circulation 2008, 117:503-511.
18. Zitterman A., Schleithoff S.S., Koerfer R. Putting cardiovascular disease and vitamin D insufficiency into perspective. Br J Nutr 2005, 94:483-492.
19. Watson K.E., Abrolat M.L., Malone L.L., Hoeg J.M., Doherty T., Detrano R., et al. Active serum vitamin D levels are inversely correlated with coronary calcification. Circulation 1997, 96:1755-1760.
20. 3 concentrations and carotid artery intima-media thickness among type 2 diabetic patients. Clin Endocrinol (Oxford) 2006, 65:593-597.
21. 3 levels: a community-based study. Int J Epidemiol 1990, 19:559-563.
22. Zittermann A., Schleithoff S.S., Tenderich G., Berthold H.K., Koerfer R., Stehle P. Low vitamin D status: a contributing factor in the pathogenesis of congestive heart failure?. J Am Coll Cardiol 2003, 41:105-112.
23. Poole K.E., Loveridge N., Barker P.J., Halsall D.J., Rose C., Reeve J., et al. Reduced vitamin D in acute stroke. Stroke 2006, 37:243-245.
24. Melamed M.L., Michos E.D., Post W., Astor B. 25-hydroxyvitamin D levels and the risk of mortality in the general population. Arch Intern Med 2008, 168:1629-1637.
25. Forman J.P., Giovannucci E., Holmes M.D., Bischoff-Ferrari H.A., Tworoger S.S., Willett W.C., et al. Plasma 25-hydroxyvitamin D levels and risk of incident hypertension. Hypertension 2007, 49:1063-1069.
26. Krause R., Buhring M., Hopfenmuller W., Holick M.F., Recker R.R., Heaney R.P. Vitamin D and calcium supplementation reduces cancer risk: results of a randomized trial. Am J Clin Nutr 2007, 85:1586-1591.
27. 3 and calcium supplementation on blood pressure and parathyroid hormone levels in elderly women. J Clin Endocrinol Metab 2001, 86:1633-1637.
28. Wang L., Manson J.E., Buring J.E., Lee I.M., Sesso H.D. Dietary intake of diary products, calcium, and vitamin D and the risk of hypertension in middle aged and older women. Hypertension 2008, 51:1073-1079.
29. Schleithoff S.S., Zittermann A., Tenderich G., Berthold H.K., Stehle P., Koerfer R. Vitamin D supplementation improves cytokine profiles in patients with congestive hearth failure: a double-blind, randomized, placebo-controlled trial. Am J Clin Nutr 2006, 83:754-759.
30. Shea M.K., Booyh S.L., Massaro J.M., Jacques P.F., D'Agostino R.B., Dawson-Hughes B., et al. Vitamin K and vitamin D status: associations with inflammatory markers in the Framingham Offspring Study. Int J Epidemiol 2008, 167:313-320.
31. Timms P.M., Mannan N., Hitman G.A., Noonan K., Mills P.G., Syndercombe-Court D., et al. Circulating MMP9, vitamin D and variation in the TIMP-1 response with VDR genotype: mechanism for inflammatory damage in chronic disorders?. QJM 2002, 95:787-796.
32. Van den Berghe G., Van Roosbroeck D., Vanhove P., Wouters P.J., De Pourcq L., Bouillon R. Bone turnover in prolonged critical illness: effect of vitamin D. J Clin Endocrinol Metab 2003, 88:4623-4632.
33. Liu S., Song Y., Ford E.S., Manson J.E., Buring J.E., Ridker P.M. Dietary calcium, vitamin D, and the prevalence of metabolic syndrome in middle-aged and older U.S. women. Diabetes Care 2005, 28:2926-2932.
34. Mattila C., Knekt P., Mannisto S., Rissanen H., Laaksonen M.A., Montonen J., et al. Serum 25-hydroxyvitamin D concentrations and subsequent risk of type 2 diabetes. Diabetes Care 2007, 30:2569-2570.
35. Fryer R.M., Rakestraw P.A., Nakane M., Dixon D., Banfor P.N., Koch K.A., et al. Differential inhibition of rennin mRNA expression by paricalcitol and calcitriol in C57/BL6 mice. Nephrol Physiol 2007, 106:76-81.
36. 3 supplementation may have adverse effects on serum lipids during postmenopausal hormone replacement therapy. Eur J Endocrinol 1997, 137:495-502.
37. Fleck A. Latitude and ischaemic heart disease. Lancet 1989, 1:613.
38. Looker A.C., Dawson-Hughes B., Calvo M.S., Gunter E.W., Sahyoun N.R. Serum 25-hydroxyvitamin D status f adolescent and adults in two seasonal subpopulations from NHANES III. Bone 2002, 30:771-777.
39. Lind L., Hanni A., Lithell H., Hvarfner A., Sorensen O.H., Ljunghall S. Vitamin D is related to blood pressure and other cardiovascular risk factors in middle-aged men. Am J Hypertens 1995, 8:894-901.
40. Perez-Castrillon J.L., Vega G., Abad L., Sanz A., Chaves J., Hernandez G., et al. Effects of atorvastatin on vitamin D levels in patients with acute ischemic heart disease. Am J Cardiol 2007, 99:903-905.
41. Vitamin D supplement in early childhood and risk for type I (insulin-dependent) diabetes mellitus. Diabetologia 1999, 42:51-54. The EURODIAB Substudy 2 Study Group.
42. Zeitz U., Weber K., Soegiarto D.W., Wolf E., Balling R., Erben R.G. Impaired insulin secretory capacity in mice lacking a functional vitamin D receptor. FASEB J 2003, 17:509-511.
43. De Zeeuw D., Agarwal R., Amdhal M., Audhya M., Coyne D., Garimella T., et al. Selective vitamin D receptor activation with paracalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL Study): a randomised controlled trial. Lancet 2010, 376:1543-1551.
44. Cozzolino M., Ketteler M., Zehnder D. The vitamin D system: a crosstalk between the heart and kidney. Eur J Heart Fail 2010, 12:1031-1041.
45. Andress D. Nonclassical aspects of differential vitamin D receptor activation. Drugs 2007, 67:1999-2012.
46. London G.M., Marchais S.J., Guerin A.P., Metivier F. Arterosclerosis, vascular calcifications and cardiovascular disease in uremia. Curr Opin Nephrol Hypertens 2005, 14:525-531.
47. Reiss A.B., Glass A.D. Atherosclerosis: immune and inflammatory aspects. J Invest Med 2006, 54:123-131.